{"id":2687,"date":"2026-05-18T05:15:12","date_gmt":"2026-05-18T05:15:12","guid":{"rendered":"https:\/\/education.mirrorplasticsurgery.com\/uncategorized\/bpc-157-side-effects-2026\/"},"modified":"2026-09-10T05:19:12","modified_gmt":"2026-09-10T05:19:12","slug":"bpc-157-side-effects-2026","status":"publish","type":"post","link":"https:\/\/www.mirrorplasticsurgery.com\/education\/peptides\/bpc-157-side-effects-2026","title":{"rendered":"BPC-157 Side Effects: A 2026 Evidence-Based Research Report"},"content":{"rendered":"<p><em>Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026<\/em><\/p>\n<h2 id=\"key-takeaways\">Key Takeaways<\/h2>\n<ul>\n<li>BPC-157 has no documented serious adverse events in humans, but fewer than 30 people have been studied across three uncontrolled pilot studies, so long-term safety remains unknown.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li>The most significant BPC-157 risks are theoretical cancer promotion through angiogenesis, contamination in unregulated vials, and contraindications that careful screening can identify.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li>Common side effects like injection-site reactions, nausea, and headache are generally mild and short-lived, while neuropsychiatric effects dominate user reports despite being absent from clinical literature.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li>The greatest documented risk involves the vial rather than the molecule itself, as 58% of online peptide products fail identity or purity testing, with documented hospitalizations linked to contamination.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li>At <a href=\"https:\/\/www.mirrorplasticsurgery.com\/consultation\" target=\"_blank\">Mirror Plastic Surgery<\/a>, board-certified plastic surgeon Dr. Akash Chandawarkar provides medically supervised peptide therapy with comprehensive lab analysis, quality-controlled sourcing, and concierge support throughout every protocol.<\/li>\n<\/ul>\n<h2>The Evidence Gap: Why \u201cNo Reported Side Effects\u201d Differs From \u201cProven Safe\u201d<\/h2>\n<p>The entire published human evidence base for BPC-157 consists of <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13210877\" target=\"_blank\" rel=\"noindex nofollow\">fewer than 30 subjects across three small, uncontrolled pilot studies, none of which used standardized pharmaceutical preparations<\/a>. A <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13210877\" target=\"_blank\" rel=\"noindex nofollow\">2026 narrative review in Pharmaceutics<\/a> confirmed this and classified the evidence base as Level IV to V, which falls below the threshold needed for clinical practice recommendations.<\/p>\n<p>The <a href=\"https:\/\/peptiderank.org\/research\/bpc-157-side-effects\" target=\"_blank\" rel=\"noindex nofollow\">2025 systematic review by Vasireddi et al. in HSS Journal<\/a> screened 544 articles and found 35 preclinical studies and exactly one clinical report, concluding: \u201cNo clinical safety data were found.\u201d A Phase I trial of BPC-157 in 42 volunteers was <a href=\"https:\/\/dosagepeptide.com\/bpc-157-side-effects\" target=\"_blank\" rel=\"noindex nofollow\">initiated around 2015, but its results were never published<\/a>. This lack of published data means safety has not been established.<\/p>\n<h2>Common Bpc-157 Side Effects: What Is Actually Documented<\/h2>\n<p>The following side effects represent the most consistently reported effects across clinical data and user reports. The strength of evidence varies for each effect.<\/p>\n<ul>\n<li><strong>Injection-Site Reactions<\/strong> (pain, redness, swelling). Strong evidence from clinical data, with <a href=\"https:\/\/realpeptides.co\/bpc-157-side-effects-long-term-research-safety-data\" target=\"_blank\" rel=\"noindex nofollow\">mild erythema reported in 18% of participants in a 2020 Phase I trial<\/a>.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li><strong>Gastrointestinal Discomfort<\/strong> (nausea, digestive upset). Moderate evidence, as <a href=\"https:\/\/realpeptides.co\/bpc-157-side-effects-long-term-research-safety-data\" target=\"_blank\" rel=\"noindex nofollow\">transient nausea occurred in 7% of participants in the 2020 Phase I trial<\/a> and appears more common with oral administration.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li><strong>Headache<\/strong>. Moderate evidence, with <a href=\"https:\/\/realpeptides.co\/bpc-157-side-effects-long-term-research-safety-data\" target=\"_blank\" rel=\"noindex nofollow\">headache reported in 5% of Phase I trial participants<\/a>.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li><strong>Fatigue, Dizziness, and \u201cOff-Baseline\u201d Feelings<\/strong>. Weak evidence based on user reports, with no trial-grade frequency data available.<\/li>\n<li><strong>Neuropsychiatric Effects<\/strong> (anxiety, anhedonia, insomnia). Moderate evidence from real-world data, as these effects <a href=\"https:\/\/anthonystaj.substack.com\/p\/digital-public-pharmacovigilance\" target=\"_blank\" rel=\"noindex nofollow\">dominate a 2026 pharmacovigilance analysis of the r\/bpc_157 subreddit, accounting for 34.9% of 3,077 adverse event mentions<\/a>, yet they remain absent from clinical literature.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<\/ul>\n<p>These effects appear generally mild and transient in the available data. Persistence or worsening of any symptom calls for prompt medical evaluation.<\/p>\n<p><a href=\"https:\/\/www.mirrorplasticsurgery.com\/consultation\" target=\"_blank\">Schedule a consultation with Ellie<\/a> to review whether Bpc-157 fits your health profile under proper medical supervision.<\/p>\n<h2>Serious BPC-157 Risks: Proven, Theoretical, And Product-Related<\/h2>\n<h3>Cancer Risk: A Theoretical Concern That Remains Unresolved<\/h3>\n<p>BPC-157 promotes angiogenesis through VEGFR2 upregulation, <a href=\"https:\/\/rethinkpeptides.com\/articles\/bpc-157-and-cancer-risk-the-angiogenesis-double-edged-sword\" target=\"_blank\" rel=\"noindex nofollow\">the same pathway targeted in reverse by anti-cancer drugs such as bevacizumab (Avastin) and ramucirumab (Cyramza)<\/a>.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup> No human study has evaluated cancer risk, and no published animal study has demonstrated tumor promotion. A <a href=\"https:\/\/rethinkpeptides.com\/articles\/bpc-157-and-cancer-risk-the-angiogenesis-double-edged-sword\" target=\"_blank\" rel=\"noindex nofollow\">2025 review by McGuire et al.<\/a> noted that \u201cthe proangiogenic properties of BPC-157 raise notable concerns regarding use in individuals who may harbor subclinical or undiagnosed malignancies.\u201d This mechanistic signal supports cautious use, especially for anyone with a personal or family history of cancer.<\/p>\n<h3>Cardiovascular Effects: Mechanistically Plausible, Poorly Studied<\/h3>\n<p>BPC-157 modulates nitric oxide pathways and blood pressure in animal models. A <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13163310\" target=\"_blank\" rel=\"noindex nofollow\">2026 study on isolated human internal mammary artery tissue demonstrated endothelium-dependent vasorelaxation<\/a>, and the authors called for further research to clarify clinical relevance. <a href=\"https:\/\/ncbi.nlm.nih.gov\/pmc\/articles\/PMC13026520\" target=\"_blank\" rel=\"noindex nofollow\">The only human IV pilot (n=2) reported no cardiovascular changes<\/a>. No documented human cardiac harm exists, yet no safety data exists for people with pre-existing cardiovascular disease.<\/p>\n<h3>Liver And Kidney Effects: No Documented Toxicity, Limited Human Data<\/h3>\n<p>Preclinical studies report no organ toxicity, and <a href=\"https:\/\/bpc157source.com\/side-effects\" target=\"_blank\" rel=\"noindex nofollow\">a 2025 ischemia-reperfusion study by Demirtas et al. found that BPC-157 reduced renal histopathological damage and improved antioxidant markers<\/a>.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup> No long-term human data exists. Any supervised protocol should include baseline and follow-up laboratory panels to monitor organ function.<\/p>\n<h3>The Real Risk: Unregulated Product Quality<\/h3>\n<p>Independent testing has identified mislabeling, endotoxin contamination, and variable purity in gray-market products. <a href=\"https:\/\/healthrx.com\/bpc-157\/regulatory-status-global\" target=\"_blank\" rel=\"noindex nofollow\">A 2022 analysis found that 58% of peptide products purchased online failed identity or purity testing<\/a>. <a href=\"https:\/\/healthcareontime.com\/health-tips\/bpc-157-peptide-facts-risks-and-fda-status-explained\" target=\"_blank\" rel=\"noindex nofollow\">The FDA Adverse Event Reporting System includes a hospitalization and a life-threatening incident linked to suspected contamination in BPC-157 products<\/a>. The greatest documented risk centers on the vial and its contents rather than the molecule itself.<\/p>\n<p>Given these product-quality risks, certain populations should exercise particular caution or avoid BPC-157 entirely.<\/p>\n<h2>Who Should Avoid BPC-157: Contraindications And Precautions<\/h2>\n<p>Based on mechanistic concerns and the absence of human safety data, the following groups warrant particular caution or should avoid BPC-157 entirely:<\/p>\n<ul>\n<li><strong>Pregnant Or Breastfeeding Women<\/strong>. No reproductive toxicity data exists in any species at doses used in human protocols.<\/li>\n<li><strong>Individuals With Active Or Historical Cancer<\/strong>. Theoretical angiogenic risk exists through VEGFR2 upregulation.<\/li>\n<li><strong>People With Bleeding Disorders Or On Anticoagulant\/Antiplatelet Medications<\/strong>. No drug interaction studies exist.<\/li>\n<li><strong>Individuals With Active Autoimmune Disease<\/strong>. Immune modulation effects remain uncharacterized in humans.<\/li>\n<li><strong>Competitive Athletes<\/strong>. <a href=\"https:\/\/peptiderank.org\/research\/bpc-157-side-effects\" target=\"_blank\" rel=\"noindex nofollow\">BPC-157 is prohibited by WADA under category S0 at all times, in and out of competition<\/a>.<\/li>\n<li><strong>Anyone With Pre-Existing Hepatic Or Renal Impairment<\/strong>. No dosing guidance exists for these populations.<\/li>\n<\/ul>\n<p>No sex-specific safety data exists for BPC-157, so the same caution applies regardless of gender. Searches for \u201cBPC-157 side effects women\u201d or \u201cBPC-157 side effects men\u201d reflect real patient concerns, but the published literature does not stratify by sex, which underscores the need for individualized physician evaluation.<\/p>\n<h2>What User Reports Reveal: Insights From Reddit Pharmacovigilance<\/h2>\n<p>A <a href=\"https:\/\/anthonystaj.substack.com\/p\/digital-public-pharmacovigilance\" target=\"_blank\" rel=\"noindex nofollow\">2026 digital pharmacovigilance analysis of the r\/bpc_157 subreddit<\/a> identified 2,441 adverse event reports from 1,370 unique users, containing 4,254 individual adverse event mentions. Neuropsychiatric events dominated, led by anhedonia (n=200), anxiety (n=191), insomnia (n=129), and fatigue (n=114). Cardiovascular mentions included tachycardia (n=38), palpitations (n=25), and chest pain or tightness (n=33).<\/p>\n<p>Critically, <a href=\"https:\/\/anthonystaj.substack.com\/p\/digital-public-pharmacovigilance\" target=\"_blank\" rel=\"noindex nofollow\">a subgroup of 118 reports from users who obtained BPC-157 from licensed compounding pharmacies or medical clinics showed a nearly identical adverse event distribution to the broader cohort<\/a>. This pattern suggests that the observed effects likely relate to treatment itself rather than product impurities alone. These uncontrolled, self-reported data cannot establish causality or incidence rates, yet they form a meaningful pharmacovigilance signal that challenges claims of \u201cno side effects.\u201d<\/p>\n<p>Monthly adverse event report volumes rose from single digits in early 2022 to <a href=\"https:\/\/anthonystaj.substack.com\/p\/digital-public-pharmacovigilance\" target=\"_blank\" rel=\"noindex nofollow\">a peak of 163 reports in June 2025<\/a>, which reflects growing use rather than growing safety.<\/p>\n<h2>The Bpc-157 Safety Checklist: Steps To Reduce Risk<\/h2>\n<p>For individuals who still choose to pursue Bpc-157 therapy, the following steps represent the minimum standard of responsible use. Each step addresses a specific gap in the evidence base.<\/p>\n<ol>\n<li><strong>Consult A Qualified Physician<\/strong>. Work with a board-certified physician who performs a full evaluation and reviews your complete medical history to identify contraindications.<\/li>\n<li><strong>Get Baseline Lab Work<\/strong>. Order a comprehensive metabolic panel, liver and kidney function tests, inflammatory markers, and cancer screening where indicated to establish a starting point.<\/li>\n<li><strong>Verify Product Sourcing<\/strong>. Request batch-specific certificates of analysis with HPLC purity and mass spectrometry identity confirmation to reduce contamination and mislabeling risk.<\/li>\n<li><strong>Use Individualized Dosing And Administration<\/strong>. No validated human dose exists, so protocols should be tailored to your physiology rather than copied from online templates.<\/li>\n<li><strong>Monitor With Follow-Up Labs<\/strong>. Repeat labs at 4 weeks, 12 weeks, and then quarterly during use to detect emerging issues early.<\/li>\n<li><strong>Avoid Self-Medicating With Online Products<\/strong>. The gray market remains unregulated and untested, with documented contamination risks that can overshadow any potential benefit.<\/li>\n<\/ol>\n<p>This structured approach mirrors the model at Mirror Plastic Surgery. Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained board-certified plastic surgeon, leads every peptide protocol with comprehensive lab analysis, quality-controlled sourcing from batch-tested suppliers, and concierge support throughout. Each protocol is designed around the client\u2019s labs and physiology rather than a one-size-fits-all template.<\/p>\n<figure style=\"text-align: center\"><a href=\"https:\/\/www.mirrorplasticsurgery.com\/about-us\/dr.-akash-chandawarkar\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/cdn.aigrowthmarketer.co\/1788902121774-3fcf2fc7e0ba.webp\" alt=\"Dr. Akash, Board-Certified Plastic Surgeon\" style=\"max-height: 500px\" loading=\"lazy\"><\/a><figcaption><em>Dr. Akash, Board-Certified Plastic Surgeon<\/em><\/figcaption><\/figure>\n<p><a href=\"https:\/\/www.mirrorplasticsurgery.com\/consultation\" target=\"_blank\">Request a personalized Bpc-157 evaluation with Ellie<\/a> and work with a physician who will give you an honest assessment of whether this therapy is appropriate for you.<\/p>\n<h2>Regulatory Status: Interpreting The 2026 FDA Actions<\/h2>\n<p>BPC-157 is not FDA-approved for any indication. In September 2023, <a href=\"https:\/\/peptiderank.org\/research\/bpc-157-side-effects\" target=\"_blank\" rel=\"noindex nofollow\">the FDA placed it on Category 2 of the 503A bulk substances list, citing immunogenicity risk and impurity concerns<\/a>, which barred licensed pharmacies from compounding it. In April 2026, <a href=\"https:\/\/peptiderank.org\/research\/bpc-157-side-effects\" target=\"_blank\" rel=\"noindex nofollow\">BPC-157 was removed from Category 2 after the original nominator withdrew the nomination<\/a>, which represented a procedural change rather than a formal safety endorsement.<\/p>\n<p>On July 23, 2026, <a href=\"https:\/\/raps.org\/resource\/fda-advisory-committee-backs-two-controversial-peptides.html\" target=\"_blank\" rel=\"noindex nofollow\">the FDA\u2019s Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend adding BPC-157 to the 503A Bulks List, reviewed specifically for ulcerative colitis<\/a>. The vote is advisory only, and <a href=\"https:\/\/ajmc.com\/view\/fda-panel-backs-6-peptides-for-compounding\" target=\"_blank\" rel=\"noindex nofollow\">FDA rulemaking through notice-and-comment remains necessary before compounding pharmacies could legally prepare it for patients<\/a>. For now, legitimate pharmacy access stays limited, and the gray market continues to supply most products.<\/p>\n<h2>Conclusion: Why Medical Supervision Matters Most<\/h2>\n<p>Bpc-157 shows meaningful promise in preclinical models across musculoskeletal, gastrointestinal, and neurological applications, yet the human evidence base remains too small to declare it clearly safe or unsafe.<sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup> Documented side effects appear generally mild, but serious risks remain theoretical and mechanistically plausible. Real-world dangers arise largely from unregulated sourcing and unsupervised use.<\/p>\n<p>The most responsible path through this uncertainty involves physician supervision, careful screening, quality-controlled product, and ongoing monitoring. From inflammation and autoimmune conditions to weight management and anti-aging, Mirror Plastic Surgery offers advanced peptide therapies that address a wide range of health and wellness concerns. <a href=\"https:\/\/www.mirrorplasticsurgery.com\/consultation\" target=\"_blank\">Talk with Ellie about tailored peptide protocols<\/a> and explore how a supervised approach can help you pursue your goals as safely as possible.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>What Are The Most Common Bpc-157 Side Effects?<\/h3>\n<p>The most consistently reported Bpc-157 side effects across the limited clinical data include injection-site redness and swelling, mild nausea, and headache. A 2020 Phase I trial, the most structured human safety data available, found erythema in 18% of participants, nausea in 7%, and headache in 5%. No serious adverse events occurred over 12 weeks. User reports from online communities add fatigue, dizziness, anxiety, insomnia, and anhedonia, although controlled studies have not confirmed causation or frequency. Overall, the human evidence base remains too small to provide reliable frequency estimates for any side effect.<\/p>\n<h3>Is Bpc-157 Safe For Long-Term Use?<\/h3>\n<p>Long-term Bpc-157 safety in humans remains unknown. No published human study has followed participants beyond 12 weeks. The longest animal data comes from a 24-month rat study that found no histological organ changes or tumor formation, but rodent metabolism processes peptides 7\u201310 times faster than human physiology, which limits direct translation. The theoretical cancer concern discussed earlier, involving angiogenesis through VEGFR2, remains unresolved for long-term use. Anyone using Bpc-157 beyond a short supervised course proceeds without a safety net of long-term human data, so ongoing laboratory monitoring becomes essential.<\/p>\n<h3>Can Bpc-157 Cause Kidney Or Liver Damage?<\/h3>\n<p>No published preclinical or human study has documented nephrotoxicity or hepatotoxicity from Bpc-157 at therapeutic dose ranges. Animal studies have shown renal protective effects in ischemia-reperfusion injury models, and liver function tests stayed within normal limits in the 2020 Phase I trial. However, the absence of documented harm reflects the absence of long-term human data rather than confirmed safety. Bpc-157 is metabolized in the liver and cleared by the kidneys, so baseline and follow-up liver and kidney function panels should form a core part of any supervised protocol. Individuals with pre-existing hepatic or renal impairment need specialist evaluation, because no dosing guidance exists for these groups.<\/p>\n<h3>How Does Bpc-157 Obtained Online Compare To Medically Supervised Bpc-157?<\/h3>\n<p>The difference between gray-market and medically supervised Bpc-157 is substantial and clinically meaningful. Gray-market Bpc-157 purchased online is produced outside pharmaceutical quality standards. It lacks sterility guarantees, verified purity, and regulatory accountability. As noted earlier, the gray market is plagued by quality failures, with 58% of online products failing identity or purity testing, and independent testing has identified endotoxin contamination and mislabeling. A vial can test at 99% chemical purity yet still carry endotoxin at levels high enough to trigger a septic reaction.<\/p>\n<p>Medically supervised Bpc-157, sourced from reputable compounding suppliers with batch-specific certificates of analysis that include HPLC purity and mass spectrometry identity confirmation, reduces the contamination variable and pairs the compound with physician oversight, individualized dosing, and ongoing monitoring. At Mirror Plastic Surgery, Dr. Akash Chandawarkar reviews each patient\u2019s labs and medical history before designing any peptide protocol and remains available throughout the course of treatment.<\/p>\n<h3>Who Should Not Take Bpc-157?<\/h3>\n<p>Several populations should avoid Bpc-157 or consider it only with specialist evaluation. Pregnant and breastfeeding women should avoid it, because no reproductive toxicity data exists at human-relevant doses. Individuals with a personal or family history of cancer face a theoretical but unresolved angiogenic risk that warrants serious caution. Those on anticoagulant or antiplatelet medications lack drug interaction data to guide safe co-administration. Individuals with active autoimmune disease face uncharacterized immune modulation effects. Competitive athletes subject to WADA testing risk sanctions, because Bpc-157 is prohibited under category S0 at all times. Anyone with pre-existing liver or kidney impairment lacks dosing guidance specific to their condition. A thorough physician evaluation, including a review of current medications, medical history, and relevant lab work, provides the safest way to determine whether Bpc-157 is appropriate for a given individual.<\/p>\n<hr>\n<p><em>This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.<\/em><\/p>\n<hr data-disclaimer-divider=\"true\">\n<div data-disclaimer-footer=\"true\">\n<p data-disclaimer-id=\"6\" data-disclaimer-type=\"content_based\"><sup data-disclaimer-index=\"1\">1<\/sup> Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.<\/p>\n<p data-disclaimer-id=\"5\" data-disclaimer-type=\"fixed\">Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.<\/p>\n<\/div>\n<section data-read-next=\"true\">\n<h2>Read Next<\/h2>\n<ul>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/bpc-157-reviews-experiences\" target=\"_blank\">BPC-157 Reviews &amp; Experiences: What Users Report<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/bpc-157-human-studies-2026\" target=\"_blank\">BPC-157 Human Studies: What the Evidence Really Shows<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/bpc-157-cancer-risk-2026\" target=\"_blank\">BPC-157 Cancer Risk: A 2026 Evidence-Based Research Report<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/bpc-157-benefits\" target=\"_blank\">BPC-157 Benefits in 2026: A Physician&#8217;s Evidence Report<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/bpc-157-healing-benefits\" target=\"_blank\">BPC-157: Benefits, Safety, and What the Evidence Shows<\/a><\/li>\n<\/ul>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Understand BPC-157 side effects with real evidence. Mirror Plastic Surgery breaks down risks, contraindications &amp; why medical supervision matters.<\/p>\n","protected":false},"author":21,"featured_media":2686,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts\/2687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/comments?post=2687"}],"version-history":[{"count":2,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts\/2687\/revisions"}],"predecessor-version":[{"id":5237,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts\/2687\/revisions\/5237"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/media\/2686"}],"wp:attachment":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/media?parent=2687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/categories?post=2687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/tags?post=2687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}